Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Zelboraf

(ZEL-boh-raf)
A drug used to treat Erdheim-Chester disease (a very rare type of histiocytosis) and advanced melanoma that have a certain mutation (change) in the BRAF gene. It is also being studied in the treatment of other types of cancer. Zelboraf blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Also called BRAF (V600E) kinase inhibitor RO5185426, PLX4032, RG7204, and vemurafenib.
More Information
Search NCI's Dictionary of Cancer Terms